Published in Br J Clin Pharmacol on March 01, 2014
Corrected QT (QTc) Study With Flucticasone Furoate and GW642444 | NCT01209026
Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol (2016) 0.81
Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. Pharmacotherapy (2015) 0.78
Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med (2015) 0.76
Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.75
Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. Eur J Drug Metab Pharmacokinet (2016) 0.75
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87
Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest (2004) 3.38
Lung volumes and forced ventilatory flows. Eur Respir J (1993) 3.00
Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol (2001) 2.55
The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol (2009) 2.26
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther (2008) 1.80
Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med (2012) 1.57
Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med (2010) 1.55
QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol (2002) 1.46
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J (2012) 1.36
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med (2013) 1.31
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol (2009) 1.25
Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther (2012) 1.19
Past, present and future--beta2-adrenoceptor agonists in asthma management. Respir Med (2005) 1.13
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med (2013) 1.12
Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med (2012) 1.09
Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet (2013) 1.06
Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med (2012) 1.03
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest (2012) 1.02
Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos (2008) 1.00
Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med (2011) 0.98
QT intervals at heart rates from 50 to 120 beats per minute during 24-hour electrocardiographic recordings in 100 healthy men. Effects of atenolol. Circulation (1992) 0.96
Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res (2011) 0.95
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy (2008) 0.95
Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos (2012) 0.93
Emerging inhaled bronchodilators: an update. Eur Respir J (2009) 0.91
Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation. Clin Ther (2006) 0.91
Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther (2012) 0.88
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist. Core Evid (2010) 0.84
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol (2013) 0.82
A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies. J Biopharm Stat (2008) 0.78
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med (2013) 1.41
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med (2013) 1.31
Cardiovascular events in patients with COPD: TORCH study results. Thorax (2010) 1.25
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med (2014) 1.20
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med (2013) 1.12
Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther (2012) 1.06
The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J (2012) 1.03
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest (2012) 1.02
Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos (2008) 1.00
Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA). Value Health (2012) 1.00
Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease. Health Qual Life Outcomes (2013) 0.95
Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol (2006) 0.93
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J (2013) 0.91
Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab (2013) 0.91
Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr (2005) 0.90
The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther (2013) 0.89
Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open (2013) 0.88
Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc (2006) 0.86
Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J Pediatr (2006) 0.85
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol (2013) 0.82
Escherichia coli isolate for studying colonization of the mouse intestine and its application to two-component signaling knockouts. J Bacteriol (2014) 0.82
Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids. Ann Allergy Asthma Immunol (2006) 0.81
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. Int J Clin Pharmacol Ther (2015) 0.80
Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. Ann Allergy Asthma Immunol (2004) 0.80
Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol (2002) 0.79
Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products. Ann Allergy Asthma Immunol (2008) 0.78
Enhanced detection of RNA from paraffin-embedded tissue using a panel of truncated gene-specific primers for reverse transcription. Biotechniques (2004) 0.78
Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2014) 0.78
Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. J Asthma (2005) 0.77
School-based indicated prevention: a randomised trial of group therapy. J Child Psychol Psychiatry (2002) 0.77
A new focus on assessing and treating asthma control in the African-American community: a call to action. J Natl Med Assoc (2008) 0.76
Tobacco control: consensus report of the National Medical Association. J Natl Med Assoc (2002) 0.75
Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Curr Med Res Opin (2015) 0.75
Acknowledge the NCT. Pract Midwife (2011) 0.75
Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. Int J Clin Pharmacol Ther (2016) 0.75
Utilization of failure mode effects analysis in trauma patient registration. Qual Manag Health Care (2007) 0.75
Best practices for managing quality and safety of foreign particles in orally inhaled and nasal drug products, and an evaluation of clinical relevance. Pharm Res (2007) 0.75
Are you prepared to deal with a high-risk respiratory illness? J Emerg Nurs (2007) 0.75